Luhua (Michael) Wang
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Luhua (Michael) Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04990778 · Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaM.D. Anderson Cancer Center · withdrawn · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator
- N/ANCT04872413 · Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialM.D. Anderson Cancer Center · completed · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator
- Ph2NCT04765111 · Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT04189757 · Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT03946878 · Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive · principal investigator
- Ph2NCT03710772 · Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT03282396 · Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT03232307 · Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaM.D. Anderson Cancer Center · withdrawn · CCND1 Positive, CD20-Positive Neoplastic Cells Present, Mantle Cell Lymphoma · principal investigator
- Early Ph1NCT03219047 · Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell LymphomaM.D. Anderson Cancer Center · completed · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator
- Ph2NCT02427620 · Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02420795 · Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaM.D. Anderson Cancer Center · terminated · Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma · principal investigator
- Ph1NCT02095834 · Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaM.D. Anderson Cancer Center · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT01946152 · Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaM.D. Anderson Cancer Center · terminated · Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT00477412 · Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaM.D. Anderson Cancer Center · completed · Mantle Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03232307
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:12 UTC. The ranking covers the 200 most relevant of 3845 PubMed records, and a shared surname and initials can bring in a namesake. All 3845 on PubMed
- 245 citationsRCR 50.5
- 163 citationsRCR 28.4
- Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.Ann Oncol · 202586 citationsRCR 18.3
- 83 citationsRCR 27.3
- Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment.Signal Transduct Target Ther · 202579 citationsRCR 22.2
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.N Engl J Med · 202674 citationsRCR 37.0
- Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Insomnia Disorder: A Randomized Clinical Trial.JAMA Netw Open · 202468 citationsRCR 14.7
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.N Engl J Med · 202556 citationsRCR 16.3
- 46 citationsRCR 23.1
- A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.N Engl J Med · 202545 citationsRCR 11.9